Johnson & Johnson reported strong full-year earnings with a 6.8% increase in net income and continued growth in their consumer and medical devices segments, despite challenges in pharmaceuticals due to generic competition and currency fluctuations. Management maintained an optimistic outlook for 2009, emphasizing strategic growth initiatives and cost management. This positive performance and forward-looking guidance are likely to bolster investor confidence in the short term.

[1]